Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1 4Phase NA 2Phase 3 2Phase 1/2 2Phase 4 1

Status

Recruiting 11Active not recruiting 11Completed 4Not yet recruiting 3Unknown 2Terminated 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Bronchial Neoplasms 1Brain Neoplasms 1

Interventions

Cisplatin 130Radiotherapy 94Carboplatin 85Paclitaxel 78Fluorouracil 78Cyclophosphamide 77Gemcitabine 72Capecitabine 66Docetaxel 65Doxorubicin 60Oxaliplatin 59Etoposide 57Leucovorin 49Vincristine 47Chemotherapy, Adjuvant 42Cytarabine 38Dexamethasone 35Drug Therapy 33Bevacizumab 30Epirubicin 29Neoadjuvant Therapy 28Pemetrexed 27Tamoxifen 25Prednisone 24Irinotecan 24Rituximab 21Methotrexate 21Radiotherapy, Intensity-Modulated 19apatinib 18Vinorelbine 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Unknown × osimertinib × Clear all
NCT05104281 2023-03-29

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Qingdao Central Hospital

Phase 3 Unknown
60 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02972333 2016-11-23

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Shandong Cancer Hospital and Institute

Phase 3 Unknown
150 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡